Drug Trial Radar · NCT02194400
Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Dec 9, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jul 2014
Primary completion
Nov 2015
Study completion Nov 2015
Sponsor
- Lead sponsor
- Resolve TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 18, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A one month multi-dose study will evaluate the safety and tolerability of 3 intravenous infusions of RSLV-132 in subjects with inactive to mild SLE.
Conditions
- Systemic Lupus Erythematosus
Interventions
RSLV-132Biological
0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: 30 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research of West Florida
Clearwater, Florida
West Michigan Rheumatology
Grand Rapids, Michigan
Altoona Center for Clinical Research
Duncansville, Pennsylvania
Metroplex Clinical Research
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.